2. Cancer
  3. Cancer Immunotherapy

Cancer Immunotherapy

Cancer immunotherapy (CIT) is a type of biological therapy, aiming to improve anti-tumor immune responses with fewer off-target effects than chemotherapy. Several types of immunotherapy include: oncolytic virus therapies, cancer vaccines, cytokine therapies, adoptive cell transfer (ACT), and immune checkpoint inhibitors (ICIs). In particular, ICIs and ACT have obtained immense clinical response, but their efficacy varies from person to person. Immune cells can be harnessed to eliminate tumor cells, such as T cells, B cells, NK cells, and myeloid cells. T cells have potent tumor-killing capability, therefore, a plethora of cancer immunotherapy research have focused on inducing T-cell-mediated anti-tumor responses. CTLA-4 and PD-1 are found on the cell surface of T cells as co-inhibitory receptors. The breakthrough in cancer immunotherapy results from the identification and subsequent targeting of checkpoint mechanisms in T cells with monoclonal antibodies against CTLA-4 and programmed death-ligand 1/programmed death-1 (PD-L1/PD-1).

Several types of cancers (e.g., melanoma, mismatch repair-deficient cancers, bladder cancer, and non-small cell lung cancer) have achieved significant clinical responses in T-cell checkpoint blockade therapies. However, single-mode immunotherapy faces challenges such as low immune response, low tumor infiltration, and complex immunosuppressive tumor microenvironment. Recently, combined therapies based on tumor immunity have received extensive attention in the research of enhancing tumor cells immunogenicity and inhibiting their growth. For example, anti CTLA-4 and PD-1, immune checkpoint blockade (ICB) combined with chemotherapy, anti-angiogenic drugs and kinase inhibitors.

Cancer Immunotherapy Related Products (13082):

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-100576
    NH125 278603-08-0 99.63%
    NH125 is a potent and selective inhibitor of eukaryotic elongation factor 2 kinase (eEF-2K/CaMKIII) with an IC50 of 60 nM for eEF-2K. NH125 kills methicillin-resistant S. aureus (MRSA) persisters by interacting with and disrupting membranes.
    NH125
  • HY-N0060B
    (E)-Ferulic acid 537-98-4 99.82%
    (E)-Ferulic acid is an isomer of ferulic acid, an aromatic compound abundant in plant cell walls. (E)-Ferulic acid causes phosphorylation of β-catenin (β-catenin), leading to proteasome degradation, increasing the expression of pro-apoptotic factor Bax and reducing pro-apoptotic factor Expression of the survival factor survivin. (E)-Ferulic acid can effectively remove reactive oxygen species (ROS) and inhibit lipid peroxidation. (E)-Ferulic acid exerts antiproliferative and antimigratory effects in the human lung cancer cell line H1299.
    (E)-Ferulic acid
  • HY-162250
    MS8847 3050872-59-5 99.78%
    MS8847 is a PROTAC degrader and antiproliferative agent targeting EZH2 (DC50=34.4 nM in EOL-1 MLL-rAML cells). MS8847 recruits the E3 ligase von Hippel-Lindau (VHL) to mediate the degradation of EZH2 via the ubiquitin-proteasome system. MS8847 induces antiproliferative effects in MLL-rearranged acute myeloid leukemia cells and inhibits the growth of triple-negative breast cancer cell lines or 3D triple-negative breast cancer models. MS8847 is applicable to research related to MLL-rearranged acute myeloid leukemia and triple-negative breast cancer.
    MS8847
  • HY-100556
    Tie2 kinase inhibitor 1 948557-43-5 99.80%
    Tie2 kinase inhibitor 1 (compound 5) is a potent, selective Tie2 kinase inhibitor with an IC50 of 250 nM. Tie2 kinase inhibitor 1 has anti-cancer activity.
    Tie2 kinase inhibitor 1
  • HY-N0704
    Agrimol B 55576-66-4 99.75%
    Agrimol B, a polyphenol, is an orally active and potent SIRT1 activator. Agrimol B shows anti-adipogenic and anticancer activity. Agrimol B shows antibacterial activity against plant pathogens. Agrimol B dramatically inhibits 3T3-L1 adipocyte differentiation by reducing PPARγ, C/EBPα, FAS, UCP-1, and apoE expression. The action of Agrimol B on the cancer cells is likely derived from its effect on c-MYC, SKP2 and p27.
    Agrimol B
  • HY-119272
    EF24 342808-40-6 99.34%
    EF24, a curcumin analogue, is an NF-kB inhibitor with great anti-tumor efficacy and oral bioavailability via deactivation of the MAPK/ERK signaling pathway in oral squamous cell carcinoma (OSCC). EF24 is active against melanoma and breast cancer cell lines with GI50 values of 0.7 μM and 0.8 μM, respectively. EF24 induces cell cycle arrest and apoptosis in MDA-MB-231 human breast cancer cells and DU-145 human prostate cancer cells. EF24 increases the levels of activated caspase 3 and 9, and decreases the phosphorylated forms of MEK1 and ERK.
    EF24
  • HY-15892
    CK-636 442632-72-6 99.94%
    CK-636 is a cell permeable inhibitor of Arp2/3 complex, that could inhibit actin polymerization, with IC50 values of 4 μM, 24 μM and 32 μM for human, fission yeast and bovine, respectively. CK636 blocks cell migration.
    CK-636
  • HY-N0404
    Sinigrin 3952-98-5 99.97%
    Sinigrin (Allyl-glucosinolate) is an orally active glucosinolate found in cruciferous plants. Sinigrin possesses multiple activities such as anti-cancer, antibacterial, antifungal, anti-inflammatory, antioxidant, and inhibition of fat synthesis. Sinigrin can be used in the research of tumors, inflammatory, and metabolic diseases.
    Sinigrin
  • HY-139643
    CXCR7 antagonist-1 1613021-99-0 99.85%
    CXCR7 antagonist-1 is a CXCR7 antagonist that inhibits the binding of the SDF-1 chemokine (also known as the CXCL12 chemokine) or I-TAC (also known as CXCL11) to the chemokine receptor CXCR7. CXCR7 antagonist-1 is useful in preventing tumor cell proliferation, tumor formation, inflammatory diseases, and many other diseases.
    CXCR7 antagonist-1
  • HY-148057
    TCO-PEG4-VC-PAB-MMAE 2758671-45-1 99.30%
    TCO-PEG4-VC-PAB-MMAE is a agent-linker conjugate for ADC. TCO-PEG4-VC-PAB-MMAE contains a cleavable ADC linker (TCO-PEG4-VC-PA) and a potent tubulin inhibitor MMAE (HY-15162). TCO-PEG4-VC-PAB-MMAE is a click chemistry reagent, it contains a TCO group that can undergo an inverse electron demand Diels-Alder reaction (iEDDA) with molecules containing Tetrazine groups.
    TCO-PEG4-VC-PAB-MMAE
  • HY-153863
    MS934 2756323-15-4 98.48%
    MS934 is a novel improved VHL-recruiting MEK 1/2 PROTAC degrader. MS934 also degrades CRAF. MS934 can be used for the research of variety of human cancers, such as melanoma, nonsmall cell lung cancer (NSCLC), colorectal cancer, primary brain tumors, and hepatocellular carcinoma (Pink: Target protein ligand (HY-168288); Black: linker (HY-168289); Blue: E3 ligase ligand (HY-112078)).
    MS934
  • HY-119917
    Gossypetin 489-35-0 99.82%
    Gossypetin is a hexahydroxylated flavonoid and is a potent mitogen-activated protein kinase kinase (MKK)3 and MKK6 inhibitor with strongly attenuates the MKK3/6-p38 signaling pathway, has various pharmacological activities, including antioxidant, antibacterial and anticancer activities.
    Gossypetin
  • HY-17010
    Retapamulin 224452-66-8 98.0%
    Retapamulin (SB-275833) is a topical antibiotic that binds Staphylococcus aureus and E. coli ribosomes with a Kd of 3 nM. Retapamulin can be used in researches of atopic dermatitis and prostate cancer.
    Retapamulin
  • HY-N6966
    Ethyl Caffeate 102-37-4 99.34%
    Ethyl Caffeate is a natural phenolic compound isolated from Bidens pilosa. Ethyl caffeate suppresses NF-κB activation and its downstream inflammatory mediators, inducible nitric oxide synthase (iNOS), cyclooxygenase-2 (COX-2), and prostaglandin E2 (PGE2) in vitro or in mouse skin.
    Ethyl Caffeate
  • HY-N0826
    Corynoline 18797-79-0 98.84%
    Corynoline is an orally active acetylcholinesterase (AChE) inhibitor with an IC50 of 30.6 μM. Corynoline exhibits multiple activities including anti-inflammatory, antinociceptive, antitumor and analgesic effects. Corynoline can be used in the research of diseases such as tumors and inflammatory pain.
    Corynoline
  • HY-N4118
    Cephaeline 483-17-0 99.77%
    Cephaeline ((-)-Cephaeline), a desmethyl analog of Emetine, is a phenolic alkaloid in Indian Ipecac roots isolated from the Cephaelis ipecacuanha. Cephaeline exhibits potent inhibition of both Zika virus (ZIKV) and Ebola virus (EBOV) infections. Cephaeline is an inductor of histone H3 acetylation and an inhibitor of mucoepidermoid carcinoma cancer stem cells (MEC), which promotes ferroptosis by inhibiting NRF2 to exert anti-lung cancer efficacy.
    Cephaeline
  • HY-110137
    Furamidine dihydrochloride 55368-40-6 ≥99.0%
    Furamidine dihydrochloride (DB75 dihydrochloride) is a selective protein arginine methyltransferase 1 (PRMT1) inhibitor with an IC50 of 9.4 μM. Furamidine dihydrochloride is selective for PRMT1 over PRMT5, PRMT6, and PRMT4 (CARM1) (IC50s of 166 µM, 283 µM, and >400 µM, respectively). Furamidine dihydrochloride is a potent, reversible and competitive tyrosyl-DNA phosphodiesterase 1 (TDP-1) inhibitor. Inhibition of TDP-1 by Furamidine dihydrochloride is effective both with single- and double-stranded DNA substrates but is slightly stronger with the duplex DNA. Furamidine dihydrochloride is also an antiparasite agent.
    Furamidine dihydrochloride
  • HY-B0157A
    Ketotifen fumarate 34580-14-8 99.88%
    Ketotifen (HC 20-511) fumarate is an orally active second-generation noncompetitive histamine 1 (H1) receptor blocker and mast cell stabilizer. Ketotifen fumarate can block 6-phosphogluconate dehydrogenase (PGD) in vitro. Ketotifen fumarate also has antiviral activity against SARS-CoV-2 and Influenza virus. Ketotifen fumarate can be used to the research of autoimmune encephalomyelitis (EAE) and asthma attack prevention.
    Ketotifen fumarate
  • HY-B0656
    Rabeprazole 117976-89-3 99.14%
    Rabeprazole (LY307640) is a second-generation proton pump inhibitor (PPI) that irreversibly inactivates gastric H+/K+-ATPase. Rabeprazole induces apoptosis. Rabeprazole acts as an uridine nucleoside ribohydrolase (UNH) inhibitor with an IC50 of 0.3 μM. Rabeprazole can be used for the research of gastric ulcerations and gastroesophageal reflux.
    Rabeprazole
  • HY-107390
    AX-024 1370544-73-2 99.73%
    AX-024 is an orally available, first-in-class inhibitor of the TCR-Nck interaction that selectively inhibits TCR-triggered T cell activation with an IC50 ~1 nM. AX-024 modulates cell signaling by targeting SH3 domains. AX-024 has low-acute toxicity and high potency and selectivity, and strongly inhibit the production of IL-6, TNF-α, IFN-γ, IL-10 and IL-17A.
    AX-024